Facebook
X
LinkedIn
ForwardBones of Contention: Navigating Innovations in Real-World Management of Non-Spine Bone Metastases (PRO 03)
This activity is designed for radiation oncologists, focusing on managing bone metastases. One of the three presentations exclusively explores stereotactic body radiation therapy (SBRT) for non-spinal bone metastases. Supporting data guides discussions on SBRT's effectiveness and strategies. We highlight clinical situations that support SBRT and share insights on appropriate retreatment regimens. In addition, we cover the role of external beam radiation therapy (EBRT/XRT) in prophylactic treatment for bone metastases, highlighting patient selection, preferred dose fractionation, and treatment volumes. The activity also addresses how to navigate peer-to-peer advocacy during the treatment approval process and alternative treatment strategies. Attendees gain comprehensive insights into non-spinal bone metastasis management, refining their therapeutic strategies and enhancing patient care through evidence-based practices.
Target Audience
This activity is designed to meet the interests of radiation oncologists.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Discuss the role of stereotactic body radiation therapy (SBRT) in managing non-spinal bone metastases, identifying key indications and expected outcomes.
- Discuss the role of prophylactic radiation therapy to prevent skeletal-related events.
- Evaluate supporting data that justifies the use of RT in various clinical situations and develop effective communication strategies for peer-to-peer interactions regarding treatment approval, as well as alternative treatment strategies.
- Christopher Hays Pope, MD, is employed by CARTI.
- Winston Vuong, MD, is employed by UW Medicine.
- Jonathan T. Yang, MD, PhD, is employed by New York University School of Medicine. Dr. Yang receives grant/research funding and compensation from AstraZeneca, Cantex Therapeutics, Debiopharm, Kazia Therapeutics, Nanocan Therapeutics and Plus Therapeutics. Dr. Yang owns stock options in Nanocan Therapeutics.
- Zachary A. Kohutek, MD, PhD, is employed by Vanderbilt University Medical Center.
All relevant financial relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
Available Credit
- 1.25 AMA PRA Category 1 Credit™
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.